Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. BioLargo, Inc.
  6. Summary
    BLGO   US09065A1007

BIOLARGO, INC.

(BLGO)
Delayed OTC Markets  -  03:51 2022-09-30 pm EDT
0.2708 USD   -6.25%
08/16Biolargo : Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Published in Quarterly Report
PU
08/15BIOLARGO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/15BioLargo, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
 SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
0.2686(c) 0.2601(c) 0.2505(c) 0.2888(c) 0.27075(c) Last
257 723 479 907 213 276 311 004 71 002 Volume
-4.04% -3.16% -3.69% +15.29% -6.25% Change
More quotes
Estimated financial data (e) (USD)
Sales 2020 2,43 M - -
Net income 2020 -8,43 M - -
Net Debt 2020 2,46 M - -
P/E ratio 2020 -2,86x
Yield 2020 -
Sales 2021 2,53 M - -
Net income 2021 -7,08 M - -
Net Debt 2021 0,17 M - -
P/E ratio 2021 -7,41x
Yield 2021 -
Capitalization 73,4 M 73,4 M -
EV / Sales 2020 12,3x
EV / Sales 2021 21,9x
Nbr of Employees 31
Free-Float 84,5%
More Financials
Company
BioLargo, Inc. is a technology developer and environmental engineering company. The Company invents, develops, and commercializes platform technologies to solve environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds (VOC) control, air quality control and infection control. It provides sustainable solutions... 
Sector
Commodity Chemicals
Calendar
11/18Earnings Release
More about the company
All news about BIOLARGO, INC.
08/16Biolargo : Achieves 185% Growth to $1.3 Million Revenue for Second Quarter 2022, as Publis..
PU
08/15BIOLARGO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/15BioLargo, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun..
CI
08/12Biolargo : Q2 2022 Earnings Results Webcast and Conference Call on Wednesday, August 17, 2..
PU
08/11Biolargo : Secures First PFAS Mitigation Customer and Signs New Channel Partner for PFAS R..
PU
08/05BioLargo Announces Revenue Results for the Second Quarter of 2022
CI
08/05Biolargo : Sets New Quarterly Revenue Record - Form 8-K
PU
08/05Biolargo, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/03Biolargo : Sets New Quarterly Revenue Record
PU
06/07Biolargo, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submissi..
AQ
06/02Biolargo, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/31BioLargo to Present at the LD Micro Invitational XII Investor Conference on June 7-9, 2..
NE
05/23BioLargo, Inc. Discusses Record-Breaking Quarter on The Stock Day Podcast
NE
05/19Biolargo, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/16BIOLARGO, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
More news
News in other languages on BIOLARGO, INC.
08/15BioLargo, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clos le ..
05/16BioLargo, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
03/31BioLargo, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre ..
03/31BioLargo, Inc. Le vérificateur remet en question la continuité de l'entreprise
2021BioLargo, Inc. annonce ses résultats pour le troisième trimestre et les neuf mois termi..
More news
Chart BIOLARGO, INC.
Duration : Period :
BioLargo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Dennis P. Calvert Chairman, President & Chief Executive Officer
Charles K. Dargan Chief Financial Officer
Kenneth Reay Code Director & Chief Science Officer
Joseph L. Provenzano Secretary, Director & Executive VP-Operations
Dennis E. Marshall Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOLARGO, INC.27.59%73
SAUDI BASIC INDUSTRIES CORPORATION-23.45%70 879
AIR LIQUIDE-15.44%58 960
WANHUA CHEMICAL GROUP CO., LTD.-8.81%39 460
ALBEMARLE CORPORATION13.12%31 091
LYONDELLBASELL INDUSTRIES N.V.-18.38%24 403